BR112012030930A2 - fatores de trevo (tff) para tratamento de doenças pulmonares crônicas. - Google Patents

fatores de trevo (tff) para tratamento de doenças pulmonares crônicas.

Info

Publication number
BR112012030930A2
BR112012030930A2 BR112012030930A BR112012030930A BR112012030930A2 BR 112012030930 A2 BR112012030930 A2 BR 112012030930A2 BR 112012030930 A BR112012030930 A BR 112012030930A BR 112012030930 A BR112012030930 A BR 112012030930A BR 112012030930 A2 BR112012030930 A2 BR 112012030930A2
Authority
BR
Brazil
Prior art keywords
pneumonia
tff
clover
factors
treatment
Prior art date
Application number
BR112012030930A
Other languages
English (en)
Inventor
Fiala Kaare
Heslet Lars
Original Assignee
Trifoilium Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trifoilium Aps filed Critical Trifoilium Aps
Publication of BR112012030930A2 publication Critical patent/BR112012030930A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Abstract

fatores de trevo (tff) para o tratamento de doenças pulmonares crônicas. a presente invenção proporciona métodos para melhorar ou induzir um reparo epitelial pelas vias aéreas e/ou regeneração e/ou para a normalização da remodelação das vias aéreas epiteliais, usando uma deposição de um ou mais fatores pró-regenerativos, preferencilamente um peptídeo ou proteína da família de fator familiar de trevo (tff). o fator pró-regenerativo é administrado a um paciente como um tratamento de doenças pulmonares obstrutivas crônicas (copd), bronquite crônica, fibrose cística, asma, bronquiectasia, panbronquiolite, pneumonia, pneumonia associada a ventilação (vap), pneumonia adquirida em hospital (hap), pneumonia adquirida na comunidade (cap), pneumonia adquirida na comunidade grave (scap) e pneumonia carinii ou para pacientes que sofrem de danos pulmonares reduzindo a função do sistema de transporte mucociliar com base no funcionamento completo dos cílios secundários para, por exemplo, a inalação de gases tóxicos. a presente invenção também proporciona uma terapia e ou profilática ou preventiva, isto é, profilaxia com base em um grupo pré-definido de pacientes do tipo intervenções em pacientes fumantes a fim de aumentar o contínuo reparo das vias aéreas epiteliais e/ou a regeneração dos cílios respiratórios melhorando a folga mucociliar. o fator pró-regenerativo é administrado intra-traqueal, intra-bronqueal, intra-alveolar ou brônquio-alveolar. a administração, por exemplo, através de inalação de um aerosol ou como um pó e/ou administrado como uma lavagem bronco-alveolar (bal) uma quantidade eficaz do agente.
BR112012030930A 2010-06-04 2011-06-03 fatores de trevo (tff) para tratamento de doenças pulmonares crônicas. BR112012030930A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201070247 2010-06-04
PCT/DK2011/050197 WO2011150944A1 (en) 2010-06-04 2011-06-03 Trefoil factors (tff) for the treatment of chronic pulmonary diseases

Publications (1)

Publication Number Publication Date
BR112012030930A2 true BR112012030930A2 (pt) 2017-07-11

Family

ID=44532503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030930A BR112012030930A2 (pt) 2010-06-04 2011-06-03 fatores de trevo (tff) para tratamento de doenças pulmonares crônicas.

Country Status (8)

Country Link
US (1) US20130274171A1 (pt)
EP (1) EP2575864A1 (pt)
JP (1) JP2013537168A (pt)
CN (1) CN103096917A (pt)
AU (1) AU2011260713A1 (pt)
BR (1) BR112012030930A2 (pt)
RU (1) RU2012156256A (pt)
WO (1) WO2011150944A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348739A (zh) * 2015-08-31 2018-07-31 墨卡托医疗系统公司 用于治疗哮喘的药物的局部施用
CN105582526B (zh) * 2016-02-25 2020-07-17 山东睿鹰制药集团有限公司 三叶因子2在制备治疗及预防肺/支气管急性炎症疾病药物方面的应用
CA3036553A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
CA3152665A1 (en) * 2019-08-27 2021-03-04 Tonix Pharma Limited Modified tff2 polypeptides
US20230173028A1 (en) * 2020-03-30 2023-06-08 Shandong Ruiying Pioneer Pharmaceutical Co., Ltd Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DE69131867T2 (de) 1990-03-23 2000-05-18 Minnesota Mining & Mfg Anwendung von löslichen fluorhaltigen Tensiden zur Herstellung von Aerosol-Präparaten mit dosierter Abgabe
CN1070867C (zh) 1994-08-26 2001-09-12 诺沃挪第克公司 三叶形肽双体
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
AU2002315234A1 (en) * 2001-06-14 2003-01-02 Novo Nordisk A/S Mucosal repair by tff2 peptides
EP1461076A4 (en) * 2001-11-28 2005-03-09 Gen Hospital Corp METHODS AND COMPOSITIONS FOR TREATING LESIONS OF RESPIRATORY EPITHELIUM
US20030215431A1 (en) * 2002-02-11 2003-11-20 Lars Thim Management of mucosal viscosity by TFF monomer peptides
EP1581623A2 (en) * 2002-10-31 2005-10-05 The GI Company, Inc Trefoil domain-containing polypeptides and uses thereof
EP1587534A1 (en) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
NZ556158A (en) 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same

Also Published As

Publication number Publication date
EP2575864A1 (en) 2013-04-10
JP2013537168A (ja) 2013-09-30
WO2011150944A1 (en) 2011-12-08
CN103096917A (zh) 2013-05-08
US20130274171A1 (en) 2013-10-17
AU2011260713A1 (en) 2013-01-10
RU2012156256A (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
BR112012030930A2 (pt) fatores de trevo (tff) para tratamento de doenças pulmonares crônicas.
WO2012047674A3 (en) Methods and compositions for disease treatment using inhalation
Alkotaji Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
BR112014027681A2 (pt) preparações de agentes terapêuticos hidrofóbicos, métodos de fabricação e uso dos mesmos
BR112013004416A2 (pt) agente terapêutico para enfisema pulmonar
PE20190406A1 (es) Composiciones farmaceuticas que comprenden bromuro de aclidinio
MD4369C1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
US20100196285A1 (en) Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
CY1117758T1 (el) Κουμπι επιστομιου εισπνευστηρα ξηρας κονεως
HRP20160630T1 (hr) Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
EA201201391A1 (ru) Ингалятор
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
BR112017003731A2 (pt) composições e métodos para prevenir ou tratar doenças, condições ou processos distinguidos por proliferação anormal de fibroblasto e deposição de matriz extracelular
Goetz et al. Mucus clearance strategies in mechanically ventilated patients
Riethmueller et al. Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
BR112017014861A2 (pt) ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?
EA201591871A1 (ru) Фармацевтическая композиция, содержащая будесонид и формотерол
BR112012023877A2 (pt) dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal
BR112022020403A2 (pt) Composições e métodos para tratar complicações de infecções virais e outros transtornos repiratórios
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
US9636350B2 (en) Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]